Compare PAAI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAAI | TENX |
|---|---|---|
| Founded | 1990 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 81.1M |
| IPO Year | 2017 | 2001 |
| Metric | PAAI | TENX |
|---|---|---|
| Price | $0.62 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.29 |
| AVG Volume (30 Days) | 143.5K | ★ 1.6M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,892,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.46 | N/A |
| 52 Week Low | $0.61 | $1.31 |
| 52 Week High | $3.47 | $19.40 |
| Indicator | PAAI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 42.62 |
| Support Level | N/A | $1.34 |
| Resistance Level | $0.99 | $2.01 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 26.12 |
Paradium.AI Inc is an AI technology company. The group operates as a centralized, AI-optimized infrastructure that puts the tools, data, and reach media entrepreneurs could never build alone directly into their hands. Its products are Infosentience, Encore, and Cutter Studios.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.